近日,银诺医药宣布,依苏帕格鲁肽α注射液减重II期临床研究于7月初圆满完成所有患者入组,取得了临床研究的阶段性进展!本研究(chinadrugtrials.org, CTR20240801)是一项“依苏帕格鲁肽α注射液在饮食和运动干预后体重控制不佳的超重及肥胖受试者”中的临床研究,经国家药品监督管理局的批准,由中国工程院院士、上海交通...
GLP-1受体激动剂(GLP-1RA)在降糖的同时更能带来明确的心血管获益,即主要心血管不良事件发生风险显著降低,引领了糖尿病管理从血糖管理到整体化管理的治疗理念改变,更成为国内外指南一致推荐的ASCVD合并2型糖尿病(T2DM)全程治疗的一线药物。 为进一步探讨GLP-1 RA在临床中的应用,“第二届诺和诺德心血管代谢峰会”(NNC...
GLP-1具有葡萄糖浓度依赖性降糖作用,其受体激动剂(GLP-1 RA)能模拟GLP-1的生理作用,是治疗糖尿病与肥胖症的重要药物。此外,GLP-1 RA亦对心血管系统、肾脏、中枢神经系统等有保护作用。 图表1:GLP-1的生物学机制(来源:Anti-obesity drug discove...
一直到2024年3月14日,Madrigal Pharmaceuticals旗下药物瑞司美替罗(Rezdiffra)成为FDA获批的首个NASH上市药物,用于治疗伴有肝纤维化的非酒精性脂肪性肝炎成人患者,这一千亿市场的序幕才真正被拉开。 瑞司美替罗是一种选择性甲状腺激素受体-β(THR-β)激动剂。它通过模拟甲状腺激素在肝脏中的作用,调节脂质代谢,从而...
GLP-1具有葡萄糖浓度依赖性降糖作用,其受体激动剂(GLP-1 RA)能模拟GLP-1的生理作用,是治疗糖尿病与肥胖症的重要药物。此外,GLP-1 RA亦对心血管系统、肾脏、中枢神经系统等有保护作用。 图表1:GLP-1的生物学机制(来源:Anti-obesity drug discovery: advances and challenges.Nature Reviews)...
With the FDA approval of the first specific drug for MASH in March, Madrigal’s Rezdiffra is a pioneer in a market that is set for rapid change. ByBen AdamsNov 5, 2024 10:02am Pharma Novo Nordisk's semaglutide delivers in phase 3 MASH study ...
(2002/09/01 − 2022/12/01). A total of 417,322 patients with AKI-D were discharged from the hospital. After exclusions, 165,860 AKD patients were identified, comprising 7,511 GLP-1 RA users and 158,349 nonusers. PSM resulted in 7,492 patients in each group. Five-year follow-up ...
This drug also produces significant weight decrement. Mean baseline body weight was 91–93 kg which was significantly decreased by 3.73 kg with 0.5 mg, 4.53 kg with 1 mg, and non-significantly decreased in placebo with only 0.98 kg. The most important reported side effects...
另外,对于2型糖尿病患者,GLP-1 RA优于胰岛素;如已用胰岛素,建议联用GLP-1 RA,以获得更大的疗效和持久性。 糖尿病筛查年龄提早至35岁 关于糖尿病前期和糖尿病的筛查,新版诊疗标准中一个最显著的变化是,将全人群开始筛查的年龄从45岁提早至35岁。 即所有人从35岁起,不论是否有肥胖等糖尿病危险因素,均应开始筛...
A composition may also be used in the formulation of controlled, sustained, protracting, retarded, and/or slow release drug delivery systems. Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal, or intravenous injection by means of a syringe, optionally a pen-like...